These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

162 related articles for article (PubMed ID: 19886861)

  • 1. Aldose reductase inhibition: emerging drug target for the treatment of cardiovascular complications.
    Reddy AB; Ramana KV
    Recent Pat Cardiovasc Drug Discov; 2010 Jan; 5(1):25-32. PubMed ID: 19886861
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Aldose Reductase: An Emerging Target for Development of Interventions for Diabetic Cardiovascular Complications.
    Jannapureddy S; Sharma M; Yepuri G; Schmidt AM; Ramasamy R
    Front Endocrinol (Lausanne); 2021; 12():636267. PubMed ID: 33776930
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Aldose reductase, oxidative stress, and diabetic mellitus.
    Tang WH; Martin KA; Hwa J
    Front Pharmacol; 2012; 3():87. PubMed ID: 22582044
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Updates on Aldose Reductase Inhibitors for Management of Diabetic Complications and Non-diabetic Diseases.
    Grewal AS; Bhardwaj S; Pandita D; Lather V; Sekhon BS
    Mini Rev Med Chem; 2016; 16(2):120-62. PubMed ID: 26349493
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Role of aldose reductase and oxidative damage in diabetes and the consequent potential for therapeutic options.
    Srivastava SK; Ramana KV; Bhatnagar A
    Endocr Rev; 2005 May; 26(3):380-92. PubMed ID: 15814847
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Central role for aldose reductase pathway in myocardial ischemic injury.
    Hwang YC; Kaneko M; Bakr S; Liao H; Lu Y; Lewis ER; Yan S; Ii S; Itakura M; Rui L; Skopicki H; Homma S; Schmidt AM; Oates PJ; Szabolcs M; Ramasamy R
    FASEB J; 2004 Aug; 18(11):1192-9. PubMed ID: 15284219
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Recent studies of aldose reductase enzyme inhibition for diabetic complications.
    Suzen S; Buyukbingol E
    Curr Med Chem; 2003 Aug; 10(15):1329-52. PubMed ID: 12871133
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Aldose reductase inhibitors: 2013-present.
    Quattrini L; La Motta C
    Expert Opin Ther Pat; 2019 Mar; 29(3):199-213. PubMed ID: 30760060
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Aldose reductase and AGE-RAGE pathways: key players in myocardial ischemic injury.
    Kaneko M; Bucciarelli L; Hwang YC; Lee L; Yan SF; Schmidt AM; Ramasamy R
    Ann N Y Acad Sci; 2005 Jun; 1043():702-9. PubMed ID: 16037296
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Sorbinil, an Aldose Reductase Inhibitor, in Fighting Against Diabetic Complications.
    Huang Q; Liu Q; Ouyang D
    Med Chem; 2019; 15(1):3-7. PubMed ID: 29792152
    [TBL] [Abstract][Full Text] [Related]  

  • 11. CADD Studies in the Discovery of Potential ARI (Aldose Reductase Inhibitors) Agents for the Treatment of Diabetic Complications.
    Gupta SK; Tripathi PK
    Curr Diabetes Rev; 2023; 19(9):e180822207672. PubMed ID: 35993470
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Aldose reductase, oxidative stress and diabetic cardiovascular complications.
    Vedantham S; Ananthakrishnan R; Schmidt AM; Ramasamy R
    Cardiovasc Hematol Agents Med Chem; 2012 Sep; 10(3):234-40. PubMed ID: 22632267
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Aldose reductase: a novel target for cardioprotective interventions.
    Ramasamy R
    Curr Drug Targets; 2003 Nov; 4(8):625-32. PubMed ID: 14577653
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Dietary sources of aldose reductase inhibitors: prospects for alleviating diabetic complications.
    Saraswat M; Muthenna P; Suryanarayana P; Petrash JM; Reddy GB
    Asia Pac J Clin Nutr; 2008; 17(4):558-65. PubMed ID: 19114390
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Aldose reductase inhibition ameliorates the detrimental effect of estrogen replacement therapy on neuropathology in diabetic rats subjected to transient forebrain ischemia.
    Shen B; Vetri F; Mao L; Xu HL; Paisansathan C; Pelligrino DA
    Brain Res; 2010 Jun; 1342():118-26. PubMed ID: 20417192
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Development of Aldose Reductase Inhibitors for the Treatment of Inflammatory Disorders and Cancer: Current Drug Design Strategies and Future Directions.
    Sonowal H; Ramana KV
    Curr Med Chem; 2021; 28(19):3683-3712. PubMed ID: 33109031
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Protective effect of Tephrosia purpurea in diabetic cataract through aldose reductase inhibitory activity.
    Bhadada SV; Vyas VK; Goyal RK
    Biomed Pharmacother; 2016 Oct; 83():221-228. PubMed ID: 27372406
    [TBL] [Abstract][Full Text] [Related]  

  • 18. N-(Aroyl)-N-(arylmethyloxy)-α-alanines: Selective inhibitors of aldose reductase.
    Nencetti S; La Motta C; Rossello A; Sartini S; Nuti E; Ciccone L; Orlandini E
    Bioorg Med Chem; 2017 Jun; 25(12):3068-3076. PubMed ID: 28392277
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Aldose reductase: a key player in myocardial ischemic injury.
    Kaneko M; Ramasamy R
    Exerc Sport Sci Rev; 2004 Jan; 32(1):19-23. PubMed ID: 14748545
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Targeting aldose reductase for the treatment of diabetes complications and inflammatory diseases: new insights and future directions.
    Maccari R; Ottanà R
    J Med Chem; 2015 Mar; 58(5):2047-67. PubMed ID: 25375908
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.